.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Merck
Medtronic
QuintilesIMS
Express Scripts
Novartis
Dow
Fish and Richardson
Colorcon
Baxter

Generated: December 17, 2017

DrugPatentWatch Database Preview

Forest Labs Inc Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS INC, and what generic alternatives to FOREST LABS INC drugs are available?

FOREST LABS INC has ten approved drugs.

There are ten US patents protecting FOREST LABS INC drugs on FOREST LABS INC drugs in the past three years.

There are eighty-two patent family members on FOREST LABS INC drugs in thirty-five countries.

Summary for Forest Labs Inc

International Patents:82
US Patents:10
Tradenames:10
Ingredients:6
NDAs:10
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs IncFETZIMAlevomilnacipran hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL204168-002Jul 25, 2013RXYesNo► Subscribe► SubscribeYY► Subscribe
Forest Labs IncFETZIMAlevomilnacipran hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL204168-003Jul 25, 2013RXYesNo► Subscribe► SubscribeYY► Subscribe
Forest Labs IncFETZIMAlevomilnacipran hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL204168-001Jul 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-004Aug 27, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-001Aug 27, 2009RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs IncFETZIMAlevomilnacipran hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL204168-001Jul 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-001Aug 27, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs IncBENTYL PRESERVATIVE FREEdicyclomine hydrochlorideINJECTABLE;INJECTION008370-002Oct 15, 1984APRXYesYes► Subscribe► Subscribe► Subscribe
Forest Labs IncBENTYLdicyclomine hydrochlorideINJECTABLE;INJECTION008370-001Oct 15, 1984APRXYesYes► Subscribe► Subscribe► Subscribe
Forest Labs IncURSO FORTEursodiolTABLET;ORAL020675-002Jul 21, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs IncRECTIVnitroglycerinOINTMENT;INTRA-ANAL021359-001Jun 21, 2011► Subscribe► Subscribe
Forest Labs IncURSO FORTEursodiolTABLET;ORAL020675-002Jul 21, 2004► Subscribe► Subscribe
Forest Labs IncURSO 250ursodiolTABLET;ORAL020675-001Dec 10, 1997► Subscribe► Subscribe
Forest Labs IncCARAFATEsucralfateTABLET;ORAL018333-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FOREST LABS INC drugs

Drugname Dosage Strength Tradename Submissiondate
levomilnacipranExtended-release Capsules20 mg, 40 mg, 80 mg and 120 mgFETZIMA7/25/2017

Non-Orange Book Patents for Forest Labs Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,229Methods of producing stable pancreatic enzyme compositions► Subscribe
9,259,403Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide► Subscribe
7,005,452Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug► Subscribe
7,074,833Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Inc Drugs

Country Document Number Estimated Expiration
Portugal1601349► Subscribe
Denmark1601349► Subscribe
Poland219671► Subscribe
Taiwan201422233► Subscribe
World Intellectual Property Organization (WIPO)2011057176► Subscribe
Austria401872► Subscribe
New Zealand598477► Subscribe
Russian Federation2005128548► Subscribe
Japan2013510176► Subscribe
Malaysia163469► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Dow
UBS
Mallinckrodt
McKinsey
Daiichi Sankyo
Accenture
Boehringer Ingelheim
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot